Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-11-22 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：第三届监事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of a resolution passed at a supervisory board meeting of Shanghai Medicilon Inc. It details the meeting date, attendance, and the approval of a proposal regarding a change in the company's actual controller's commitment. It references compliance with regulatory guidelines and legal provisions. The document is short (791 characters) and serves as a formal announcement of a board/management decision rather than a full report or detailed financial disclosure. It does not contain financial statements or detailed management discussion but focuses on governance and supervisory board decisions. Therefore, it fits best under Board/Management Information (MANG).
2022-11-22 Chinese
美迪西：关于相关股东签署附条件生效的《一致行动关系解除协议》以及附条件生效的《一致行动协议》暨实际控制人拟变更的提示性公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement regarding the signing of conditional agreements to terminate and establish new 'acting-in-concert' relationships among major shareholders, resulting in a change of the company's actual controller. It includes specifics about shareholdings, board influence, and the impact of these changes on company control. The document is a formal disclosure about changes in the company's controlling shareholders and their agreements, which directly affects the company's control structure. There is no financial data, earnings information, or report publication notice. The content fits the category of announcements about changes in the company's board or senior management or control structure. Therefore, the document is best classified as 'Board/Management Information' (MANG).
2022-11-22 Chinese
美迪西：关于实际控制人变更承诺的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Medicilon Inc. regarding changes in the commitments made by the actual controllers of the company. It details changes in shareholder commitments, control rights, and voting rights, including the withdrawal of one controller and the resulting change in control structure. The document includes board and supervisory committee approvals and independent director opinions. It is not a financial report, earnings release, or audit report. It is not a proxy solicitation or voting results announcement. The content focuses on changes in control commitments and related disclosures, which aligns with regulatory announcements about shareholder commitments and control changes. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory disclosure about changes in shareholder commitments and control, not a formal report or financial statement.
2022-11-22 Chinese
美迪西：独立董事关于第三届董事会第十二次会议相关事项的独立意见
Regulatory Filings
2022-11-22 Chinese
美迪西：关于收到上海证券交易所问询函的公告
Regulatory Filings Classification · 100% confidence The document is an official announcement from Shanghai Medicilon Inc. regarding receipt of an inquiry letter from the Shanghai Stock Exchange. The inquiry concerns changes in the company's actual controlling shareholders and related shareholder agreements, requests for detailed disclosures, and compliance with listing rules. The document is a regulatory announcement responding to a regulatory inquiry, not a financial report or detailed management discussion. It does not contain financial statements or detailed financial data, nor is it a report publication announcement. It is a regulatory filing informing the market about the inquiry and the company's commitment to respond. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-11-22 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司实际控制人变更承诺的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding changes in the actual controller's commitment of a listed company. It discusses changes in shareholder commitments, control rights, and related board and supervisory approvals. It references regulatory guidelines and includes formal opinions from independent directors and the supervisory board. The document is not a financial report, earnings release, or a simple announcement but a regulatory compliance and governance-related filing about changes in control commitments. This fits best under Regulatory Filings (RNS) as it is a compliance and disclosure document that does not fit other specific categories like MANG (management changes) or DVA (voting results). The document length is under 5,000 characters, but it contains substantive content rather than just announcing a report publication, so it is not RPA. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2022-11-22 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.